Attenuation of scopolamine-induced cognitive dysfunction by obovatol
暂无分享,去创建一个
Sun Young Lee | S. Nam | J. Hong | S. Han | D. Choi | K. Oh | Hyun Hee Lee | Yoot-Mo Lee | Young‐Jung Lee | Im Seop Choi
[1] Jae Woong Lee,et al. Obovatol improves cognitive functions in animal models for Alzheimer’s disease , 2012, Journal of neurochemistry.
[2] Dong Hyun Kim,et al. The ameliorating effects of stigmasterol on scopolamine-induced memory impairments in mice. , 2012, European journal of pharmacology.
[3] Jae Woong Lee,et al. Obovatol attenuates LPS-induced memory impairments in mice via inhibition of NF-κB signaling pathway , 2012, Neurochemistry International.
[4] S. Aid,et al. Inhibition of NADPH oxidase promotes alternative and anti‐inflammatory microglial activation during neuroinflammation , 2012, Journal of neurochemistry.
[5] I. Uriarte-Pueyo,et al. Flavonoids as acetylcholinesterase inhibitors. , 2011, Current medicinal chemistry.
[6] I. Shim,et al. Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats. , 2011, Journal of microbiology and biotechnology.
[7] N. Greig,et al. Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons , 2011, PloS one.
[8] G. Superti-Furga,et al. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. , 2011, Bioorganic & medicinal chemistry.
[9] Jae-Hwang Jeong,et al. Neurotrophic activity of obovatol on the cultured embryonic rat neuronal cells by increase of neurotrophin release through activation of ERK pathway. , 2010, European journal of pharmacology.
[10] Hyoung‐Chun Kim,et al. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. , 2010, European journal of pharmacology.
[11] K. Suk,et al. Obovatol attenuates microglia‐mediated neuroinflammation by modulating redox regulation , 2010, British journal of pharmacology.
[12] H. Okada,et al. Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice , 2009, Brain Research.
[13] S. Mandel,et al. Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties , 2009, Genes & Nutrition.
[14] Y. Yun,et al. Neurite Outgrowth Effect of 4-O-methylhonokiol by Induction of Neurotrophic Factors Through ERK Activation , 2009, Neurochemical Research.
[15] S. Nam,et al. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity , 2009, Journal of Natural Medicines.
[16] T. Ahmed,et al. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease , 2009, Pharmacology Biochemistry and Behavior.
[17] R. Vassar,et al. The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease Pathophysiology* , 2008, Journal of Biological Chemistry.
[18] C. Glabe,et al. Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.
[19] Yeong-Rim Kang,et al. Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis. , 2008, Bioorganic & medicinal chemistry.
[20] J. Hong,et al. Anxiolytic-like effects of obovatol isolated from Magnolia obovata: Involvement of GABA/benzodiazepine receptors complex , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[21] R. Schliebs,et al. Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein , 2006, International Journal of Developmental Neuroscience.
[22] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[23] R. Quirion,et al. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.
[24] C. C. Lin,et al. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis , 2001, Phytotherapy research : PTR.
[25] J. Growdon,et al. Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.
[26] J. Growdon,et al. The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease , 2000, Annals of neurology.
[27] T. Deacon,et al. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system , 1998, Neuroreport.
[28] R. Nitsch,et al. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. , 1997, Life sciences.
[29] E. Giacobini,et al. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex , 1993, Neuropharmacology.
[30] E. Giacobini,et al. Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum , 1993, Neuropharmacology.
[31] J. Growdon,et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.
[32] S. M. Stahl,et al. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man , 1988, Journal of psychopharmacology.
[33] N. Butters,et al. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. , 1986, Behavioral and neural biology.
[34] R. Petersen,et al. Scopolamine induced learning failures in man , 1977, Psychopharmacology.
[35] K. Courtney,et al. A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.
[36] V. Guillén,et al. Cholinesterase inhibitors in the treatment of Alzheimer's disease , 2013 .
[37] R. Quirion,et al. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. , 2002, Progress in neurobiology.
[38] E. Mutschler,et al. WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties. , 1993, Life sciences.